News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clovis Oncology (CLVS) Announces Pricing Of $250 Million Of Convertible Senior Notes


9/4/2014 12:36:52 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of $250 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Clovis Oncology has also granted the initial purchasers a 30-day option to purchase up to $37.5 million aggregate principal amount of additional notes on the same terms and conditions.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES